Latest: Oligonucleotide handling and stability
Latest: Early Detection Summit heads to London in March 2023
Latest: Maximizing in vivo models: Employing long-term rodent telemetry for disease efficacy and...
Latest: Nitrogen carrier gas: A viable alternative to helium
Latest: Mass spectrometry webinars that you won't want to miss
Latest: Get involved in our festive reviews giveaway!
Latest: How Analytik Jena's technologies safeguard the circular economy of valuable metals
Full meeting agenda announced: Virtual Analytical Summit 2023
Oligonucleotide handling and stability
Systec presents: The efficient Systec Connect software package for autoclaves of the Systec...
CytoSMART Technologies joins the Axion BioSystems brand
Mass spectrometry webinars that you won't want to miss
The importance of protein biomarkers in drug development: A roundtable discussion
Managing the risk of nitrosamines in medicinal drugs
Your essential guide to preparative LC
Systec Connect DS: For Systec HX-Series & Systec HX-Series 2D autoclaves
CLARIOstar Brochure
NEPHELOstar<sup>®</sup> Plus: Laser-Based Microplate Nephelometer for Light Scattering Detection
PHERAstar<sup>®</sup> FSX Product Brochure
Multiplexing Technology
Water Purification
Microscopy
Biophysical Characterization Technology
Liquid Handling
HPLC Technology
SLAS 2023 Building Biology...
20 Apr 23 - 21 Apr 23
In this application note, Waters demonstrates the use of Xevo™ G3 QTof platform to perform a comparability analysis for infliximab innovator Remicade® and three biosimilars (Inflectra®, Avsola®, and Renflexis®).
Download this Article
Xevo TQ MS
waters_connect
Advertisement